Treating Ulcerative Colitis: Generic vs. Brand-Name Medicine

Erin Matlock, who struggles with ulcerative colitis, one day opened her Delzicol capsule to find her pervious medication inside.

The Bulletin, a newspaper in Central Oregon, published a piece about Matlock?s change in medication titled, ?Blocking generics.?? This piece examines the financial benefits pharmaceutical companies gain from patenting new prescriptions just before they face competition from generic manufacturers: ?With no new clinical trials, the company secured an expedited review from the FDA and got Delzicol approved six months before Asacol was due to go off-patent. ?By pulling Asacol from the market, they could get doctors to begin writing prescriptions for Delzicol and patients established on it well before a generic Asacol arrived.?

For years, Matlock took Asacol to help treat her condition.? Until it stopped being manufactured.? Her doctor told her about a new prescription from the same manufacturer called Delzicol.? Now she has the choice between taking twelve Delzicol pills (which she finds more difficult to digest) a day and spending $25 a month or taking four Apriso pills (another mesalamine-based medicine) a day while paying $125 dollars a month.

Matlock?s struggles are not uncommon.? Many patients who suffer from ulcerative colitis require medication, and even surgery, to treat their symptoms.

Although there is no known cure, correctly applied therapy has been known to markedly reduce symptoms and even lead to long-term remission.

Herman & Wallace offered their first on Bowel Pathology and Function in Stony Brook, NY last April and is in the midst of confirming dates for another course in 2014.? Keep a look out for updates!